The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Program-non-specific Funding, 2009LRRK2 Variation in Parkinson's Disease
Objective/Rationale:
Over the last decade genetic causes of Parkinson’s disease have given great insights into the pathways and mechanisms that play a role in the disease. The discovery of common... -
Program-non-specific Funding, 2009Delivery of Kinase-Modified LRRK2 to Dopaminergic Neurons Using High-Capacity Viral Vectors
Promising Outcomes of Original Grant:
Mutations in LRRK2 are the most common known cause of PD, and LRRK2 demonstrates kinase-dependent neurotoxicity in vitro but these results have not been confirmed... -
Program-non-specific Funding, 2009Immunology and bio activity of regulated rAAV1-GDNF in pre-clinical models of PD
Objective/Rationale:
Clinical trials with a trophic factor called GDNF, where GDNF is injected directly in the brain by pumps, have not been completely successful. Many scientists believe that the... -
Program-non-specific Funding, 2009Time Course of TNF-alpha Expression and Oxidative Stress after Intrastriatal 6-OHDA
Objective/Rationale:
Animal models of Parkinson’s disease can provide investigators with tools to examine the causes of the disease itself as well as potential therapies for treatment. One of the most... -
MJFF Research Grant, 2009A Pre-clinical Alpha-Synuclein Model of Parkinson's Disease
Objective/Rationale:
This project will aim to establish the behavioral and neuroanatomical correlates of injecting a viral vector that overexpresses the gene for alpha-synuclein into the brains of non... -
Clinicopathological Correlations of Parkinson’s Disease, 2009Evaluation of the Enteric Nervous System in PD
Objective/Rationale:
Gastrointestinal (GI) symptoms (constipation, for example) afflict essentially every PD patient, negatively impact quality of life, and diminish effectiveness of oral medications...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.